$17.74
3.86% yesterday
Nasdaq, Dec 03, 10:18 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US80810D1037
Symbol
SDGR

Schrodinger Inc Stock price

$17.74
-2.81 13.67% 1M
-5.16 22.53% 6M
-1.55 8.04% YTD
-4.21 19.18% 1Y
+1.26 7.65% 3Y
-46.95 72.58% 5Y
-10.90 38.06% 10Y
-10.90 38.06% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.66 3.86%

New AI Insights on Schrodinger Inc Insights AI Insights on Schrodinger Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$915.6m
Net debt
positive
Cash
$391.2m
Shares outstanding
73.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.1 | 5.1
EV/Sales
3.6 | 3.6
EV/FCF
negative
P/B
4.1
Financial Health
Equity Ratio
51.2%
Return on Equity
-44.4%
ROCE
-33.5%
ROIC
-100.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$257.0m | $254.7m
EBITDA
$-164.1m | $-169.5m
EBIT
$-170.5m | $-189.4m
Net Income
$-176.0m | $-175.4m
Free Cash Flow
$-3.4m
Growth (TTM | estimate)
Revenue
32.9% | 22.7%
EBITDA
22.8% | 16.6%
EBIT
21.9% | 9.5%
Net Income
0.9% | 6.2%
Free Cash Flow
98.0%
Margin (TTM | estimate)
Gross
58.2%
EBITDA
-63.9% | -66.5%
EBIT
-66.3%
Net
-68.5% | -68.9%
Free Cash Flow
-1.3%
More
EPS
$-2.4
FCF per Share
$0.0
Short interest
24.7%
Employees
891
Rev per Employee
$230.0k
Show more

Is Schrodinger Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Schrodinger Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Schrodinger Inc forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a Schrodinger Inc forecast:

Buy
75%
Hold
25%

Financial data from Schrodinger Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
257 257
33% 33%
100%
- Direct Costs 108 108
58% 58%
42%
149 149
19% 19%
58%
- Selling and Administrative Expenses 139 139
1% 1%
54%
- Research and Development Expense 181 181
11% 11%
70%
-164 -164
23% 23%
-64%
- Depreciation and Amortization 6.35 6.35
10% 10%
2%
EBIT (Operating Income) EBIT -170 -170
22% 22%
-66%
Net Profit -176 -176
1% 1%
-68%

In millions USD.

Don't miss a Thing! We will send you all news about Schrodinger Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Schrodinger Inc Stock News

Neutral
Seeking Alpha
2 days ago
Schrodinger's shares have declined sharply in recent weeks, due largely to soft guidance for the fourth quarter. There is little reason to believe that this is anything more than a temporary headwind caused by market conditions though. In addition, recent cost reductions and the end of internal drug development should significantly reduce cash burn in 2026.
Neutral
Business Wire
28 days ago
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 19, at 4:00 p.m. GMT (11:00 a.m. ET). The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately...
Neutral
Seeking Alpha
28 days ago
Schrödinger, Inc. ( SDGR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jaren Madden - Chief Corporate Affairs Officer & Head of Investor Relations Ramy Farid - CEO, President & Director Richie Jain - Executive VP, CFO & Treasurer Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Conference Call Participants Mani Foroohar ...
More Schrodinger Inc News

Company Profile

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.

Head office United States
CEO Ramy Farid
Employees 891
Founded 1990
Website www.schrodinger.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today